China Intensive Lipid Lowering With Statins in Acute Coronary Syndrome

• Status: Unknown status
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In summary, the CHILLAS study will be the first multicenter study performed in a Chinese population using a patient-level analysis to compare the effects and safety of intensive statin therapy with that of moderate statin therapy. Therefore, it will determine whether "lower is better", that is, whether LDL cholesterol lowering to a level of approximately 100mg/dl provides a benefit inferior to that of LDL cholesterol lowering to a much lower level; examine the role of inflammatory markers in predicting cardiac events and response to statin therapy; and evaluate the effects of statin therapy on regression of coronary atherosclerosis using IVUS.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ministry of Science and Technology of the People´s Republic of China
• Treatments: Atorvastatin; Atorvastatin Calcium; Hydroxymethylglutaryl-CoA Reductase Inhibitors

Criteria

Inclusion Criteria:

• Clinical diagnosis of acute coronary syndrome

• Clinically stable for 24 hours

Exclusion Criteria:

• Hypersensitive to statins

• Receiving therapy with atorvastatin at a dose greater than 20 mg per day before enrollment or lipid-lowering therapy with fibric acid derivatives or niacin that can not be discontinued

• Having a coexisting condition that shortened expected survival to less than two years

• Having obstructive hepatobiliary disease or other serious hepatic or kidney disease

• Having an unexplained elevation in the creatine kinase level that was more than three times the upper limit of normal and that was not related to myocardial infarction

• Having undergone surgery or serious trauma within the preceding two months

• Having been in the final stage of chronic congestive heart failure

• Having a baseline level of LDL cholesterol less than 50mg/dl